You are here

Development of Transporter Targeted Platinum Drugs for Pediatric Tumor

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA183186-01
Agency Tracking Number: R43CA183186
Amount: $190,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
67 JENNINGS LN
ATHERTON, CA 94027-3017
United States
DUNS: 78401096
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 RICHARD MAMELOK
 (650) 361-1192
 apricity.therapeutics@gmail.com
Business Contact
 PROF M
Phone: (650) 361-1192
Email: apricity.therapeutics@gmail.com
Research Institution
 Stub
Abstract

Project Summary/Abstract Childhood cancers remain a leading cause of death in children between 1 and 14 years of age. Of the childhood cancers, solid tumors are among the least curable. The goal of the proposed Phase I studies will be to develop targeted anti-cancer platinum analogs to treat three childhood tumors: osteosarcoma, rhabdomyosarcoma and neuroblastoma. In the U.S. about 1600 children are diagnosed with these tumors each year with about 400 to 800 dying each year from these diseases. Cisplatin, afirst generation platinum analog, together with other drugs are used in the treatment of these solid tumors. However, cisplatin is highly toxic and causes irreversible kidney damage and hearing loss, which is especially devastating in children because itresults in lifelong difficulties in communication and learning. Moreover, high doses of cisplatin, which may be curative, cannot be administered, because of the toxicities. The three childhood cancers selected for the proposed studies have high expression

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government